LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients

Giacomina Brunetti1, Dimas C Belisario2, Sara Bortolotti3

  • 1Department of Basic and Medical Sciences, Neurosciences and Sense Organs, Section of Human Anatomy and Histology, University of Bari, Bari, Italy.

Insights

Tumor necrosis factor superfamily member 14 (TNFSF14), also known as LIGHT, drives bone loss in non-small cell lung cancer metastasis. Inhibiting LIGHT or RANKL significantly reduces osteoclast formation, suggesting LIGHT as a therapeutic target for bone metastases.

Area of Science:

  • Immunology
  • Oncology
  • Bone Biology

Background:

  • Metastatic tumors disrupt tissue microenvironment and organ homeostasis.
  • The role of Tumor Necrosis Factor Superfamily Member 14 (TNFSF14), or LIGHT, in bone metastasis requires elucidation.

Purpose of the Study:

  • To investigate the role of LIGHT in osteolytic bone disease caused by non-small cell lung cancer (NSCLC) metastasis.
  • To evaluate LIGHT as a potential therapeutic target for osteolytic bone metastases.

Main Methods:

  • Assessed LIGHT expression in monocytes and serum levels in NSCLC patients with and without bone metastasis.
  • Measured RNA expression and serum levels of RANKL in bone metastatic patients.
  • Utilized a mouse model (LLC-1 cell line) to study bone homeostasis changes in wild-type and Tnfsf14 knockout mice after intratibial implantation.

Main Results:

  • Elevated LIGHT levels in monocytes and serum of NSCLC patients with bone metastasis compared to controls.
  • Increased RANKL levels observed in bone metastatic patients.
  • Inhibition of osteoclastogenesis by anti-LIGHT or RANK-Fc in patient-derived PBMC cultures.
  • Wild-type mice with bone metastasis showed increased osteoclasts and decreased osteoblasts/osteoid formation.
  • Tnfsf14 knockout mice exhibited no significant bone loss in the metastatic model.

Conclusions:

  • LIGHT is a key regulator of bone homeostasis during metastatic invasion.
  • LIGHT promotes osteoclastogenesis, contributing to osteolytic bone disease in NSCLC.
  • LIGHT represents a promising novel therapeutic target for treating osteolytic bone metastases.

Related Concept Videos